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Abstract 
 Human cancer is the second leading cause of death in the United States and 
breast cancer is responsible for the second highest number of deaths in women with 
cancer worldwide.  Today, cancer is becoming more and more resistant to current 
chemotherapeutic agents.  In an effort to decrease this resistance, natural products like 
gossypol are being tested for efficacy as a natural chemotherapeutic agent with anti-
cancer properties.  Current literature demonstrates that gossypol is indeed an effective 
drug against breast cancer when used alone and when combined with other 
chemotherapeutic agents [1-5]. The majority of current literature focuses on the ability of 
gossypol to antagonize anti-apoptotic proteins like BCL-XL and induce apoptosis [6, 7]. 
This study helps understand previous data and goes beyond the current knowledge 
base and explores not only apoptosis induction, but also on other important effects like: 
oxidative stress, other possible avenues of cell death, growth and development, and cell 
cycle progression.  Combining physiological, genotypic, flow cytometric and biochemical 
assays, a more complete understanding of gossypol‟s efficacy and mechanism of action 
can be ascertained.  In past studies, the focus of gossypol‟s efficacy has been too 
narrow and currently the study of gene regulators like microRNAs (miRNAs) has not 
been incorporated.  This study reveals evidence that miRNA may play an important role 
and that gossypol‟s efficacy is in fact a multi-component system that is interconnected in 
its overall mechanism of action.   
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Chapter 1: Review of Breast Cancer, MCF7 Cell Line, Gossypol, MicroRNAs, 
Oxidative Stress and Cancer 
Breast Cancer 
Cancer is the second most common cause of death in the US, exceeded only by 
heart disease, accounting for nearly 1 of every 4 deaths [Cancer.org].  In 2012, about 
577,190 Americans are expected to die of cancer, more than 1,500 people a day (Table 
1) [Cancer.org]. Of these, breast cancer is the most diagnosed cancer among women, 
and the second leading cause of death in women, second only to lung cancer 
[Cancer.org].  An estimated 1,384,000 females were diagnosed with breast cancer 
globally in 2008 [8]. 
Breast cancer is screened for by mammograms in asymptomatic women in an 
attempt to diagnose at an early stage.  Early detection is important due to the strong 
correlation between stage at diagnosis and mortality [8]. Additionally, in most cases as 
the size of the tumor increases, so does the likelihood of lymph node invasion, leading 
to poor long-term survival.     
Incidence rates of breast cancer are the highest of any cancer amongst females 
in most regions of the world, with the exception of several countries in Eastern and 
Western Africa and parts of Central and South America  and Southern Asia [8].  In 
developed countries, breast cancer is almost two and a half times more common.  This 
large regional variation is thought to occur for many reasons, most of which are 
centered on lifestyle.  Women in more developed countries have fewer children, give 
birth at an older age and are less likely to breastfeed [9].  Obesity, alcohol consumption, 
use of oral contraceptives and hormone replacement therapy are other factors 
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associated with higher incidence rates in developed countries [9].  Globally, 89% 
of breast cancers are diagnosed from the age of 40 and above [10].   
Survival for breast cancer is higher than most other types of cancers.  However, 
longer term survivors experience an ongoing survival deficit due to relapses and 
metastases [8].  One of the most important determinants of survival is stage at 
diagnosis.  In the United States between 2001 and 2007, the 5-year relative survival 
percentages varied from 99% for localized tumors, 84% regional disease and 23% for 
distant stage disease [11].   
MCF-7 Cell Line 
MCF-7 cell line has proven to be a great model for human breast cancer studies 
in vitro [12]. MCF-7 is an adherent epithelial cell line that was first isolated in 1970 from 
the breast tissue of a 69-year old Caucasian woman (blood type: O, Rh positive) 
diagnosed with metastatic breast carcinoma [13].  Two mastectomies were performed, 
the first removing a tumor on the right breast determined benign and the second on the 
left breast determined malignant mammary adenocarcinoma 7 and 5 years respectively 
post diagnosis.  Local recurrences appeared on the left chest wall immediately after 
postoperative radiotherapy.  Radiotherapy and hormonotherapy controlled the 
recurrences for 3 years.  Eventually in 1970, widespread erythematous recurrences 
appeared on the left anterior chest wall of which nodules were removed and placed in 
culture.  Two months after the nodules were removed; the patient developed a pleural 
effusion.   From this pleural effusion, cells were cultured and stabilized to eventually 
become the MCF-7 cell line [13].   
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Culturing the nodules was unsuccessful due to the overgrowth of fibroblasts, but 
from the pleural effusion culture the primary cell type remained epithelial.  Eventually 
after the culture stabilized, it retained several characteristics of differentiated mammary 
epithelium, including ability to process estradiol via cytoplasmic estrogen receptors and 
the capability of forming domes.  Although this cell line expresses estrogen receptors 
they are not estrogen dependent.   The mean chromosome number for this cell line is 
85 subtetraploid composed of 26 metacentrics, 35 subtelocentrics and 18 acrocentrics 
[13].  Growth of MCF7 cells is inhibited by tumor necrosis factor alpha (TNF alpha). 
Secretion of IGFBP's can be modulated by treatment with anti-estrogens [5, 14]. MCF-7 
has an average doubling time of about 29 hours and possesses the wnt 7h+ oncogene 
[7].   
Gossypol 
 The structural composition of gossypol was identified by chemists from bulk 
samples of cottonseed oil as long ago as 1886 [15]. It has a chemical formula of: 
C30H30O8 [16]. The atropisomers (+/-) ratio varies among cotton species [17]. It is 
composed of two aldehyde, six hydroxyl, and two alkyl-naphthalene groups as seen in 
Figure 1.1. The resulting polarity from the two groups makes it soluble in many organic 
solvents like DMSO, and the alkyl-naphthalene groups are the reason its insoluble in 
water [18]. Gossypol exists in three different tautomeric forms depending on the solvent. 
In alkaline solvents, or with DMSO as a solvent, gossypol is in equilibrium between the, 
ketol, aldehyde and hemi-acetal forms [19]. Gossypol is a highly reactive molecule that 
is found in free or bound form. The bound structure is non-toxic, but can inactivate or 
reduce the bound target (e.g. enzyme). Correlating with the amino-carboxyl group 
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distance, gossypol more efficiently reacts with amino acids at PHs with a range between 
5.7-7.5 [20]. Together, these properties make gossypol a highly reactive, unstable, anti-
oxidative as well as pro-oxidative chemical. 
Gossypol exists naturally in the cotton plant, and in high concentrations within the 
cotton seeds [7].  Gossypol has many biological and agricultural properties including 
anticancer activity [7].  Gossypol has appeared previously in literature inhibiting the 
growth of several cancer cell lines in a number of ways including uncoupling oxidative 
phosphorylation [21], inhibiting cytoplasmic and mitochondrial enzymes involved in 
energy production [22], decreases in BCL-2 and BCL-XL [23-25], depletion of cellular 
ATP [26] and inhibiting key nuclear enzymes involved in DNA replication and repair like 
DNA Polymerase Alpha and topoisomerase [27, 28].  Due to its structure, gossypol acts 
as a nonspecific enzyme inhibitor in vitro and has been shown to also effect many 
cellular functions, such as ion transport, macromolecular synthesis,  and properties of 
glycolysis, lipid membranes, respiration and glucose uptake [3].Initially, gossypol was 
studied as a contraceptive agent used in China which disrupted spermatogenesis by 
inhibiting lactate dehydrogenase-X [7].  It also was found to interfere with 
steroidogenesis in testicular Leydig cells and hindered the function of primary cultures 
of Leydig and Sertoli cells [7].  Additionally, it is found to have antisteroidogenic effects 
in female reproductive cells by suppressing adenylatecyclase and 3 Rhydroxysteroid 
dehydrogenase [2]. 
MCF-7 and gossypol 
 MCF-7 has proven to be an excellent breast cancer model for cytotoxic studies 
using a variety of chemotherapeutics [29-32].  In fact, many of these studies involving 
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treatment with gossypol are focused on using the MCF-7 model [2, 3, 33].  Gossypol 
has proven to be a potent inducer of cell death in MCF-7. Its important to use the term 
cell death because gossypol has been implicated not only in apoptosis, but it is also 
known to induce autophagy and necrosis as well.   [2, 23, 34, 35].    However, global 
studies on these pathways with the inclusion of miRNAs as a possible regulator of 
gossypol‟s effects have never previously been recorded. 
ROS, Antioxidants and Cancer 
 ROS, produced in the body, play a major role in various cell-signaling pathways.  
Studies have shown that ROS generation is associated with risk factors of chronic 
diseases like: stress, tobacco, environmental pollutants, radiation, viral infection, diet 
and bacterial infection (Figure 1.3) [36, 37].  
ROS production can lead to a variety of cellular responses (Figure 1.4).  
Interestingly, although excess ROS from a variety of sources contributes to the 
formation of many cancers, they also mediate the effects of many chemotherapeutic 
agents [38].  ROS have been implicated in the chemopreventive and anti-tumor action 
of nutraceutcials derived from many natural products used in traditional medicine.  
Therefore, it is understood that there are both cancer-suppressing as well as cancer-
promoting mechanisms to reactive oxygen species [38].   
In general, ROS inducing chemotherapies are very effective initially, but with time 
cancer cells tend to develop a strong resistance to ROS through up regulation of their 
antioxidant defense system.  This resistance is mediated through enzymes like catalase 
and superoxide dismutase which scavenge free radicals and prevent damage and 
activation of apoptotic signaling pathways [39, 40].  If gossypol inhibits this resistance, 
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then combination of drug therapy with ROS inducing chemotherapeutics can overcome 
this limitation.    
ROS have been implicated as an effector resulting in multiple pathways leading 
to cell death (Figure 1.5).  Autophagy is one of the first lines of defense when cells are 
faced with oxidative stress.  In this defensive strategy, cells utilize selective lysosomal 
self-digestion of intracellular components to maintain cellular homeostasis.  However, 
when faced with higher levels of ROS, cells often resort instead to activating the 
autophagy induced cell death pathways [41-43].  ROS induced apoptosis can be 
initiated by death receptors (extrinsic pathway) [4] or through mitochondria (intrinsic 
pathway) [38].  In the extrinsic pathway, ROS are generated by the Fas ligand and are 
in turn required for Fas phosphorylation and activation [38].  Intrinsically, ROS function 
to open the permeability transition pore of mitochondria by activating pore-destabilizing 
proteins (Bcl-2-associated X protein, Bcl-2) and inhibiting pore-stabilizing proteins (Bcl-2 
and Bcl-xL) [44]. Additionally, if ROS levels are high enough, cells will undergo necrosis.  
ROS are key players in the propagation and execution phases of necrotic cell death, 
damaging proteins, lipids and DNA either directly or indirectly, which results in 
disruption of organelle and cell integrity. When cells undergo necrosis, they initiate pro-
inflammatory signaling cascades by actively releasing inflammatory cytokines and by 
emptying their contents when they lyse [45-48].  This makes it very interesting to see 
how the miRNAs in this study affect ROS mediated reactions.   
MiRNA 
Within the last 10 years, a novel gene regulator was discovered in humans. This 
discovery began in 1993 in C. elegans.  Lin-4 was shown to be involved in gene 
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regulation via an RNA-RNA antisense interaction [49].  Later, miRNAs were ubiquitously 
found in all eukaryotic organisms [50]. Currently 1100 miRNAs have been sequenced in 
humans (microRNA.org). Initially reported as a control mechanism for developmental 
timing [51], we now know their roles are much more diverse, and  extend to many 
physiological and pathophysiological processes [52-56]. 
MiRNA is a non-coding RNA that is an important regulatory molecule in both 
plants and animals. MiRNAs are ~18-22 nucleotides long and are transcribed in the 
nucleus mainly by RNA Polymerase II.  Most miRNAs seem to be solitary and are 
expressed under the control of their own promoters within the intergenic region of the 
genome [57, 58].  However, miRNAs in the introns of protein coding genes may use the 
same promoter as the proximal gene [57].     
The biogenesis of miRNAs (Figure 1.2) begins in the nucleus where they are 
transcribed into a primary miRNA (pri-miRNA)  mainly by RNA polymerase II, although a 
minor group of miRNAs associated with Alu repeats can be transcribed by RNA 
polymerase III [59].  The pri-miRNA can harbor a single pre-miRNA or a cluster of pre-
miRNAs.  In the nucleus, pri-miRNA is cleaved into miRNA precursor (pre-miRNA)  by 
the Microprocessor complex (minimally composed of Drosha and DGCR8) which 
interacts with helicases p68 and p72 [60, 61].  The pre-miRNA is exported through the 
nuclear pore complex to the cytoplasm by Exportin5/RanGTP.  Once pre-miRNA is in 
the cytoplasm, a second RNase III or “dicer” in conjunction with TRBP or PACT cleaves 
the stem of the pre-miRNA.  The miRNA duplex is then loaded into the Ago protein 
within RISC, where one half of the duplex is preferentially retained.  This complex 
contains an Ago protein and GW182, which is required for gene silencing [60, 61]. 
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 miRNAs regulate gene expression by translational repression and  mRNA 
cleavage through  binding to the 3‟ untranslated region (UTR) of a specific mRNA 
transcript [57, 59, 60].  The complementarity between the miRNA and its prospective 
mRNA will decide whether the mRNA is cleaved or translationally repressed [62].  In 
general, a fully complimentary strand will cause cleavage while a partially 
complimentary strand will induce translational inhibition (Figure 1.2).   
MiRNA and Breast Cancer 
         As one would imagine from observing the strong regulatory function of miRNA, 
current literature demonstrates that some miRNAs regulate a variety of processes 
important in cancer formation like: cell proliferation and apoptosis [15, 16].  Recently, 
like in many other cancers, breast cancers were found to have unique miRNA 
expression profiles [63].   Due to this aberrant expression, researchers are using these 
profiles as a diagnostic tool.  In fact, some studies demonstrate using circulating 
miRNAs within blood plasma to create a profile as a non-invasive and accurate method 
for diagnosing breast cancer [64, 65].   
In breast cancer, miRNAs have been shown to play an important role in many 
different important biological pathways (Figure 1.6).  A few of these which are 
interesting in the context of this study are: ESR1 (Estrogen Receptor 1) targeted by 
miR-206 which is down-regulated in breast cancer [66-68], CCND1 (Cyclin D1) targeted 
by miR-17p and miR-20a which are down-regulated in breast cancer [69, 70], 
PDCD4(Programmed Cell Death 4)[71]; targeted by miR-21 which is known to be up-
regulated in breast cancer [72, 73].   
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 Due to this differential miRNA expression in breast cancer and their influence on 
its progression or suppression, researchers have looked to miRNA as a possible 
mechanism of cancer therapies [74, 75].  There is still much to learn about the exact 
role each miRNA plays and how to manipulate their expression in order to treat breast 
cancer.  However, the aberrant expression of miRNA in breast cancer coupled with the 
abnormal expression of their corresponding targets suggests miRNA may play an 
important role in determining how breast cancer is initiated and how it progresses. 
MiRNA and Oxidative Stress 
Although well documented in plants, few studies focus on miRNAs role in 
regulating cellular antioxidant defense systems in animals.  However, many studies 
show that miRNA expression profiles indeed change in response to oxidative stress and 
help modulate the cellular response to this stress [76-78].   
In one study, miR-17* suppresed the tumorogenicity of prostate cancer via 
inhibiting mitochondrial antioxidant enzymes MnSOD (manganese superoxide 
dismutase) and GPX (glutathione peroxidase) [79].  Because of the diverse roles of 
miRNA in gene regulation and the importance of ROS mediated mechanisms in cancer 
therapy it would be interesting to study the link between miRNA and these oxidative 
stress pathways.   
   
  
Hypothesis and Objectives 
 I hypothesize that treating MCF-7 cells with gossypol not only effects cell growth, 
proliferation, cell death and cell cycle progression, but also reduces their natural 
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resistance to ROS.  In addition, I believe oxidative stress has a large role in the 
induction of this cell death and that one or several antioxidant enzymes mediating MCF-
7‟s defense against these ROS will be down-regulated via miRNA targeting.  To test this 
hypothesis, the following specific objectives will be achieved in this thesis project: 
Objective 1: Observe the effects of gossypol on cell growth, proliferation, cell cycle 
progression and cell death 
 As described in the methods section, assays will be used to demonstrate the 
deleterious effects on cells in response to varying concentrations of gossypol.  Using a 
combination of dose response assays, cell cycle analysis and gene expression data, a 
more accurate representation of gossypol‟s global inhibitory effects will be achieved.    
Objective 2: Analyze the differential expression of miRNA in response to gossypol 
First, we  performed a microarray analysis of all human miRNAs, then 5 of the most up-
regulated and 6 of the most down-regulated miRNAs were chosen for further analysis 
by qRT-PCR.   
Objective 3: Detect gossypol‟s effects on oxidative stress and the antioxidant enzymes 
involved 
qRT-PCR analysis of key genes relating to oxidative stress will be performed.  Then, 
protein assays for several of these genes will be performed to assess gossypol‟s effects 
at the protein level.  
Objective 4: Determine the relationship between the differentially expressed miRNAs, 
their targets and the global effects on each pathway studied 
Connecting gossypol‟s effects on a phenotypic, genotypic, and protein level will help 
provide a more complete picture of why gossypol is effective.  From this data, a better 
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understanding of how gossypol should be used and how miRNA is involved in its 
efficacy will be formed. 
 
  
12 
 
Table 1.1: Estimated New Cancer Cases and Deaths (US, 2012) (www.cancer.org)  
 
 Estimated New Cases Estimated Deaths 
 Both 
SexesTotal 
Male Female Both 
SexesTotal 
Male Female 
All Sites 1,638,910 848,170 790,740 577,190 301,820 275,370 
Breast 229,060 2,190 226,870 39,920 410 39,510 
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Figure 1.1: Diagram of the physical makeup of a cotton seed and the chemical structure 
of gossypol, a polyphenolic aldehyde. Image from freepatentsonline.com 
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Figure 1.2: A general overview of miRNA biogenesis. Image from wordpress.com 
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Figure 1.3: Risk Factors for ROS in Cancer [38]. This figure demonstrates both the 
intracellular and extracellular inducers of ROS. 
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Figure 1.4: Wide Spectrum of Responses to ROS [38] 
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Figure 1.5: Multiple pathways to cell death mediated by levels of ROS [80].  As shown, 
varying levels of ROS induce varying pathways to cell death.   
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Figure 1.6: Various biological pathways and their reported miRNA targeting in breast 
cancer [72]. 
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Chapter 2: Effects of Gossypol on the Growth, Proliferation, Cell Cycle 
Progression and Cell Death of MCF-7 Breast Cancer Cells 
Abstract 
 Breast cancer is the second leading cause of death for cancers among women.  
Treating breast cancer is often unsuccessful due to the resistance of the cancer to 
traditional chemotherapeutic drugs.  Throughout scientific history we have harnessed 
the power of compounds created in nature for the benefit of human health and welfare.  
Gossypol, a polyphenolic aldehyde found in high concentrations in cotton seed, shows 
great promise as a natural chemotherapeutic drug.  In this study we observed the global 
effects of treatment of MCF-7 breast cancer cells with multiple concentrations of 
gossypol 48 hours post treatment.  The dose response curve revealed a significant 
decrease in cell proliferation in a direct relationship to the concentrations of the 
treatment.  The IC50 (Inhibitory concentration 50%) value was calculated to be 4.52 µM.  
Additionally, treatments with higher concentrations contained cells that were smaller 
and rounder compared with control cells, with some cells losing their adherence ability.  
Its clear gossypol has a strong effect on the cells and to further assess these effects, 
cell cycle analysis was performed followed by qRT-PCR of key apoptotic genes to 
further illustrate the global effects of gossypol. 
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Introduction 
Chemotherapy with cytotoxic drugs and radiotherapy are common ways to treat 
and manage breast cancer.  There are a wide variety of anticancer drugs used to treat 
breast cancer, most of which are synthetic that have targets ranging from inhibiting 
topoisomerases, raising ROS, to down-regulating the ESR.  One of the major hurdles in 
treating breast cancer like most cancers, is although they may be sensitive to synthetic 
drugs initially, they gradually develop resistance to both chemotherapy and 
radiotherapy.  This resistance in part, is due to the induction of multidrug resistant 
proteins or selection of cells expressing MDRs [1].   
However, to combat this resistance, more natural chemotherapeutics are being 
used alone and in combination with synthetic drugs to overcome this resistance and 
lead to an overall more effective treatment with fewer side effects.  A wide range of 
nutraceuticals have shown great promise by targeting various aspects of tumor 
progression (Figure 2.6).   Gossypol in particular, is one such nutraceutical that has 
demonstrated the ability to reduce resistance to substances like TRAIL (and apoptosis 
inducing cytokine) through the ROS-ERK-CHOP pathway in colorectal cells [2].  
Additionally, it has been used to combat the resistance to drugs like Tamoxifen [3] and 
Cisplatin [4]. One such study noting that when treated with Tamoxifen alone MCF-7 
ADR cell growth was inhibited by 34% but when combined with gossypol reached an 
impressive 94% growth inhibition [3].   
Negating its combination therapy success and ability to reduce drug resistance, 
gossypol used alone has proven to be a potent inducer of cell death.  Its important to 
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use the term cell death because gossypol has been implicated not only in apoptosis, but 
it is also known to induce autophagy and necrosis as well [5-7].  Gossypol is a well-
established inducer of cell death and understanding the correct concentrations to use is 
important in dictating the type of cell death, as well as the efficacy of different 
combination drug therapies to be used in the future.   
Another important factor of chemotherapeutics is their abilities to target the 
regulation of the cell cycle.  Many chemotherapeutic drugs as mentioned above sole 
mechanism of action are their ability to arrest cells in particular phases of the cell cycle.  
Since being used as a contraceptive agent in China, there has been great interest in 
gossypol‟s ability to arrest different cell lines in different phases of the cell cycle.  Indeed 
literature demonstrates this ability in a variety of cell lines, of particular interest to this 
study are those arrested in the S phase [8-10].   
The aim of this study was to focus on the physiological effects of gossypol in 
combination with the gene expression profile to create a better understanding of how 
gossypol is so effective at inhibiting MCF-7 cell growth and inducing cell death.  
Hemocytometer cell counts, flow cytometry, and qRT-PCR were performed to elucidate 
the effects of gossypol on cell proliferation, cell cycle progression and induction of cell 
death.   
Materials and Methods 
Cell Line and Cell Culture 
MCF-7 breast cancer cells were purchased from ATCC and maintained at 37˚C 
in a humidified 5%CO2 and 95% air incubator. Roswell Park Memorial Institute medium 
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(RPMI) 1640 (GIBCO, Vienna, VA) media was used to culture the cells with 10% FBS 
(PAA Laboratories, Dartmouth, MA) and 4mg/ml human recombinant insulin (GIBCO). 
The media was changed at least every 48 hours, and cells were trypsinized and 
passaged once a week using 0.05% trypsin/0.02% EDTA (Sigma, St. Louis, MO).  
Gossypol Treatment and Dose Response 
Gossypol was purchased from Sigma-Aldrich (St. Louis, MO) and stored at -80˚C 
in a dark tube impermeable to light.  A stock solution of 100mM gossypol was mixed 
using DMSO as a solvent and vacuum filtered in a laminar flow hood to maintain 
sterility.  5X105 cells were plated into 12 well plates with 3 wells per treatment group 
including controls in RPMI media with 10% FBS and no antibiotics or antifungal 
compounds with a final volume of 2mL in each well.  Cells were first incubated for 24 
hours in RPMI media with no treatment to allow for adhesion and stability.  Next, cells 
were treated at varying concentrations of gossypol using DMSO as a vehicle.  To 
exclude potential effects of DMSO, 0.1% DMSO was used in both the treatment and 
vehicle control groups. After 48 h of exposure, cells were trypsinized and counted.  
Initially, 7 concentrations (500nM, 700nM, 1µM, 2µM, 3µM, 10µM) were chosen to 
assess the efficacy of gossypol and determine the IC50 and an appropriate treatment 
dosage for later assays. Upon examining this data in figure 2.1, we concluded it was 
necessary to do a smaller nM experiment (10nM, 100nM, 300nM) to determine the 
minimum concentration capable of eliciting a statistically significant change in cell ratio.     
Cell Cycle Analysis 
 Cells were treated at varying concentrations of gossypol according to the same 
procedure as the dose response experiments.  48 hours post treatment, cells were 
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trypsinized and collected.  Then, 0.7 mL of ice cold 100% ethanol was added in 0.3 mL 
cold PBS.  Cells were incubated at -20˚C for 30 minutes.  Post-incubation, cells were 
centrifuged and the supernatant was removed.  Next, 500uL of 50ug/mL propidium 
iodide staining solution containing 500 units/mL RNaseA in PBS was added to the 
pellet.  Cells were then vortexed gently and incubated at 37˚C for 30 minutes.  Finally, 
cells were incubated at room temperature for 1 hour and analyzed by a Becton Dickson 
FACScan one laser 3-color cytometer.   
RNA Extraction, Reverse Transcription, Real Time PCR 
Cells were plated and treated according to the same procedure outlined in the 
dose response section.  Post-treatment, cells were trypsinized, centrifuged, and then 
washed with PBS and the pellets were placed in 1.8mL micro centrifuge tubes.  Next, 
RNA was extracted from cells according to the instructions of the  mirVana™ miRNA 
Isolation Kit (Ambion, Austin, TX).  First, a lysis binding buffer was used to denature the 
cells and stabilize the RNA. Then, RNA was separated from DNA and other cellular 
components via acid-phenol extraction.  From this point, the sample was treated with 
molecular grade ethanol, followed by passing through a glass-filter. To improve purity, 
the filter was washed several times before eluting the RNAs with RNase free water. 
To quantify and evaluate the quality of the RNA, a  NanoDrop ND-1000 Micro-Volume 
UVVis Spectrophotometer (NanoDrop Technologies, Wilmington, DE) was used and the 
quality of the RNA was determined by the absorbance ratios of 260/280 and 260/230. 
After collecting the RNA, 200 ng RNA was reverse transcribed to cDNA using the 
TaqMan microRNA Reverse Transcription kit from Applied Biosystems (Foster City, 
CA).  For the RT primer, the poly-T primer was used to reverse transcribe protein 
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coding genes to cDNA. The reagents used for reverse transcription were: 0.15µL of 
100mM dNTPs, 0.19uL RNase inhibitor (20U/µL), 1.5µL of reverse transcription buffer 
(10X), 2µL of primer mix (1 reverse: 1 forward: 3 poly(T)), and 1 µL of multiscribe 
reverse transcriptase (50U/µL) and RNase free water depending on the concentration of 
RNA in the sample will be added to make the final 15 uL reaction volume . A thermal 
cycler was used to perform the reverse transcription according to the parameters of 16 
°C for 30 minutes followed by 42°C for30 minutes, 85°C for 5 minutes and lastly hold at 
4°C. The samples were then diluted in 85µL DNase/RNase free water to prepare the 
solution for qRT-PCR. 
To evaluate expression levels of protein coding genes, results were analyzed 
after performing qRT-PCR on 384-well-plates using the ViiA™ 7 Real-Time PCR 
System (Applied Biosystem) using SYBR Green PCR master mix created by 
SuperArray Bioscience Corp. (Frederick, MD). Reverse and forward specific primers 
were designed and used in the quantification of protein coding genes. Next qRT-PCR 
was performed where each well contained a total of 15µL of reaction mixture composed 
of the combination of 7.5µL SYBR Green master mix, 5.5µL DNase/RNase free water,  
1µL primer mix, 1µL cDNA.  qRT-PCR was performed using at least 3 biological 
replicates and 3 technical replicates each to ensure accuracy. The technical aspects of 
the qRT-PCR program started by activating the enzyme for 10 minutes at 95°C then a 
denaturation step for 15 sec at 95°C followed by an annealing/extension step for 60 
seconds at 60°C. The last 2 steps were repeated for 40 cycles.   
Results 
Proliferation of MCF-7 cells are inhibited by gossypol 
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 Gossypol inhibited MCF-7 cell growth and proliferation in a dose dependent 
manner (Figure 2.1).  The lowest observed effect concentration (LOEC) was 0.30µM. 
The IC50 and IC20 were determined to be 4.52 µM and 0.70 µM, respectively.  
Additionally, cells seemed unhealthy, smaller, rounder and many losing anchorage 
ability in a direct relationship to gossypol concentration.   
Cell Cycle analysis by Flow Cytometry 
Cell Cycle Analysis using Flow Cytometry is shown in figure 2.2.  In the vehicle 
control,  cells at different developmental stages show a  normal distribution (75.01%G1, 
14.96%G2, 10.03%S, and 1.53% apoptotic)with the highest percentage of cells in the 
G1 phase, which suggests the cells were in a normal healthy population.  At the 0.1µM 
treatment, the cell population began to respond with a sharp increase of cells in G2 
(34.31%) a drop in G1 to 61.97%, 3.71% in S followed by a slight increase in % 
apoptosis to 2.01%.  Treatment with 1µM exhibited the highest % of cells undergoing 
apoptosis (10.82%) with an additionally large increase of cells in S phase to 19.82% 
and the lowest G1 percentage of the group (55.73%) with 24.45% of cells in the G2 
phase.  At 5 µM treatment, the apoptosis data begins the downward trend of the 
biphasic curve and drops to 6.55%, followed by slight increases in G1 and decreases in 
S to 62.99% and 12.58%, respectively, G2 remained similar to the 1 µM treatment and 
was 24.43%.  Finally, to test the effects of an extreme dosage, a 10 µM treatment was 
used and elicited a surprising response.  Although the concentration was very high, the 
percentage of apoptosis was merely 0.23%, the highest percentage of cells in S phase 
(23.86%) was also in this group, indicating an arrest caused by gossypol.  A significant 
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drop in G1 and G2 now at 57.75% and 18.39% respectively also occurred, supporting 
evidence for this S phase arrest.   
qRT-PCR analysis 
 Gossypol caused differential expression of genes (Figure 2.3) involved in the 
regulation of cell cycle, proliferation, and growth and development.  ATPase is an 
enzyme that helps maintain ionic homeostasis in cells as well as contributing to the 
energy cycling of ATP.  According to figure 2.3, this gene was down-regulated in 
response to gossypol at all 4 treatment concentrations with a p value <0.001 using 3 
biological replicates.   ESR1 (Estrogen Receptor), a ligand-activated transcription factor 
is involved in several processes such as hormone binding, DNA binding, and activation 
of transcription.  We observed an across the board down-regulation of this gene in 
response to all 4 concentrations of gossypol ( p  <0.001).  GSK3α and GSK3β 
(glycogen synthase kinase 3 alpha and beta) is a multifunctional Serine/Threonine 
protein kinase that involved in regulating several regulatory proteins including glycogen 
synthase, and transcription factors, such as JUN. It also plays a role in the WNT and 
PI3K signaling pathways.  According to the data both isoforms were down-regulated in 
response to all 4 treatment concentrations (p <0.001).  Additionally, MAPK1 (mitogen 
activated protein kinase) was down regulated in a linear fashion as treatment 
concentrations of gossypol increased (Figure 2.3) with p values <0.01.  MAPK1 is 
involved in multiple pathways and control a large number of processes such as 
differentiation, proliferation, survival, development, stress response and apoptosis.  In 
contrast, expression of RB1 appears to be stimulated by gossypol with its highest fold 
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change increase at the 0.1µM treatment.  RB1 (retinoblastoma 1) is a known negative 
regulator of the cell cycle and was the first tumor suppressor gene discovered.   
Cell Death 
  Apoptotic gene expression analysis demonstrates the effects of gossypol on 
genes relating to programmed cell death (Figure 2.4).  BAK and BAX, the proteins 
required for mitochondrial permeabilizations were down-regulated slightly in response to 
all 4 concentrations of gossypol with p values <0.001.  Additionally, Caspases 6 and 7 
(executioner caspases) were downregulated in much the same way as BAK and BAX 
with similar p values <0.001.  However, with the remaining genes, at the lowest 0.1µM 
treatment group, we see an up-regulation occurring in P53, PARP1, and PUMA with p 
values of 0.004, 0.0003, 0.040 respectively.  The higher concentrations however, show 
a decrease in expression levels of these 4 genes. 
 
Discussion 
 Initially, it was important to conduct a dose response experiment to determine the 
effective dosages of gossypol and observe the physiological response of MCF-7 cells at 
these varying concentrations.  As shown in figure 2.1 gossypol elicited a statistically 
significant physiological response at concentrations as low as 300nM.  According to this 
initial dose response data, it was easy to see gossypol was inhibiting the proliferation of 
MCF-7 cells in a dose dependent manner.  Similar inhibition was observed in a study 
using gossypol as well as a gossypol derivative called gossypolone with DNA synthesis 
inhibited at concentrations of gossypol as low as 30nM in MCF-7 cells [11].  Using 
another natural polyphenol called curcumin (isolated from the the rhizome of the plant 
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Curcuma longa L.) to treat MCF-7 cells a similar dose dependent growth inhibition was 
observed measured by an MTT assay [12]. 
From this point, we assessed gossypol‟s effects on the regulation of the cell 
cycle, while simultaneously ascertaining the apoptotic effects of the drugs per the sub 
G0 population using flow cytometric analysis.  Looking at figure 2.2, we see an 
interesting biphasic relationship to % of cells undergoing apoptosis.  As the 
concentration of gossypol increases to 1µM the % of cells undergoing apoptosis 
concurrently increases to a maximum of 10.82%.  As the concentrations increase from 
1µM however, the % of apoptosis begins to decrease to 6.55% at 5µM to a barely 
registering 0.23%.  This suggests that other than apoptosis, there are other forms of cell 
death possibly at work, namely necrosis and autophagy.  Current literature 
demonstrates that gossypol indeed has the capacity to induce other forms of cell death 
like autophagy [5, 6, 13, 14] and necrosis [15-17] depending on the concentration. 
Additionally, this data provided information on how gossypol was altering the regulation 
of the cell cycle.  Based on figure 2.2 we see when MCF-7 cells treated with the higher 
concentrations of gossypol the cells tend to diverge from their normal proportions and a 
direct relationship between treatment concentration and percentages of cells in S phase 
of the cell cycle is observed.  Previous reports of gossypol induced S phase arrest 
include: CLL cells [18], HeLa cells [8, 19] and rat spermatocytes [20].  Additionally, 
similar S phase arrest was seen in treatments using TW-37 a small molecule BCL-2 
inhibitor designed based on the structure of gossypol in 7 different human pancreatic 
cell lines [21].  Other polyphenols that induced S phase arrest are: grape resveratrol in 
SK-Mel-28 melanoma cells [22], and Piceatannol, a natural analog of resveratrol [23].   
33 
 
 Analysis of genes relating to cell cycle regulation, proliferation, and growth and 
development was performed to shed light on the physiological and cell cycle regulatory 
responses elicited by gossypol at a genetic level.  As seen in figure 2.3, gossypol tends 
to down-regulate the genes involved in growth and proliferation (ATPase, ESR1, 
GSK3α, GSK3β , and MAPK1) and up-regulated RB1 almost 3 fold at the 0.1µM 
treatment. Its easy to understand how down-regulating these growth/proliferation genes 
is important in being successful in the treatment of breast cancer.  Accordingly, many 
current chemotherapeutics target these pathways specifically [24-26].  RB1 is a strong 
regulator of the cell cycle; its up-regulation indicates that MCF-7 cells cell cycle 
regulation is being affected by treatment with gossypol [27].   In response to cytotoxic 
stress, RB1 can act to inhibit DNA replication and keep cells arrested in their respective 
phases of the cell cycle [27, 28] .  The data in figure 2.2 demonstrates a clear 
manipulation of cell cycle progression in MCF-7 cells in response to gossypol treatment 
and agrees nicely with the genotypic data in figure 2.3.   
 Additionally, qRT-PCR was performed on genes related to apoptosis.  From the 
data shown in figure 2.4 we see down-regulation of Bak and Bax as well as a 
concurrent down-regulation of caspases 6 and 7.  Caspase 3 was not studied due to the 
lack of expression in MCF-7 cells [29].  This down-regulation is interesting due to the 
apparent apoptosis induction shown in figure 2.2, as well as the data from the dose 
response (Figure 2.1) combined with the physical appearance of the cells.  Similar 
caspase down-regulation was shown in a phase II study of AT-101 (gossypol) in 
chemotherapy-sensitive recurrent extensive stage small cell lung cancer (ES-SCLC) 
[30].  With the genes P53, PARP1, and PUMA we see an increase in gene expression 
34 
 
at the lower treatment concentrations, particularly the 0.1µM concentration followed by a 
down-regulation consistent with the other apoptotic genes at the higher concentrations.  
This data suggests that the mechanism by which cell death occurs may be more 
complex than previously suggested in earlier studies.  Instead of a clear cut example of 
apoptosis, it is more likely that multiple pathways to cell death are induced by treatment 
with gossypol.   
 Gossypol demonstrates strong effects on the growth, cell death, cellular 
proliferation, and cell cycle progression of MCF-7 cells.  According to the data, cell cycle 
progression, growth and development and the mediators between the two seem to be 
intertwined with the effects of gossypol on physiological change and induction of cell 
death.  It appears that the higher concentrations of gossypol are toxic to the cells.  By 
various mechanisms gossypol has been shown to induce autophagy, apoptosis and 
necrosis [2, 5-7, 31, 32]   It is well established that in many instances autophagy and 
apoptosis induced cell death are interrelated with BH3 domain containing proteins 
playing a large role in both pathways as seen in figure 2.5 [33].  Since gossypol is a 
BH3 mimetic [32], this scenario seems more likely considering the common element 
between the two pathways is Bcl-2 as seen in figure 2.5 [32, 33].  In summary, gossypol 
inhibits proliferation of MCF-7 cells, arresting them in the S phase of the cell cycle, while 
at the same time inducing cell death and gross morphological changes. (data not 
shown) 
 From the data we conclude that treating MCF-7 cells with gossypol disrupts cell 
proliferation, cell cycle progression and promotes cell death in a concentration 
dependent manner.  When analyzing these results at a physiological and genetic level, 
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we can also observe how miRNA may play a role in regulating genes that play a part in 
why gossypol is so effective.  When cells were treated with gossypol, the expressions of 
several miRNAs were shown to be altered in response (figure 3.4).  For this study we 
will focus on miR-206, miR-15b (up-regulated) and miR-96 (down-regulated).  Figure 
2.7 describes some of the pathways known to be affected by these miRNAs found 
throughout literature.  miR-206 has been shown to be a potent repressor of ESR1 [34-
36], a gene shown to be down-regulated in this study (figure 2.3).  Also found to be up-
regulated, studies have shown miR-15b targets BCL-2 [37, 38], a survival protein that is 
well established as being down-regulated in response to gossypol [6, 39, 40].  Finally, 
miRNA 96 was shown to be down-regulated in response to gossypol and has been 
associated with a targeting of the FOXO pathway [41, 42].  MiR-96 acts as an oncomir 
suppressing FOXO1 in MCF-7 cells causing levels of FOXO1 to be very low.  The 
FOXO1 transcription factor act to regulate genes involved in the apoptotic response, cell 
cycle checkpoints, and cellular metabolism and is a putative tumor suppressor [41]. 
Gossypol acts to stimulate a variety of mechanisms that synergistically contribute to its 
efficacy.  This study demonstrates a clearer picture of how gossypol acts to inhibit MCF-
7 cell proliferation and induce cell death and introduces the first evidence of gossypol‟s 
efficacy being linked to its alteration of miRNA expression.   
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Table 2.1. ICs of gossypol on MCF-7 
IC LOEC IC5 IC10 IC20 IC50 
Gossypol (nM) 300 134 
 
267 700 4520 
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Figure 2.1: The effect of gossypol on MCF-7 cell proliferation 48 hours post treatment 
(Different letters=statistically significant difference P<0.05). 
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Figure 2.2: Effect of gossypol on cell cycle. MCF-7cells post-treatment with five different 
gossypol concentrations after 48 hours  
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Figure 2.3: qRT-PCR analysis of gossypol‟s effect on the expression of protein coding 
genes related to a variety of processes including: cell cycle regulation, growth and 
development and cellular proliferation (* = p<0.05 compared to VC).  
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Figure 2.4: qRT-PCR analysis of gossypol‟s effect on genes relating to cell death.  A 
general trend of down-regulation was observed in response to gossypol.  (* = p<0.05 
compared to VC) 
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Figure 2.5: Representation of the cell death-inducing effects of BH3 mimetics.  This 
figure illustrates the dual contribution of apoptosis and autophagy to induce cell death 
mediated by BH3 mimetics [33].   
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Figure 2.6: Nutraceuticals targeting various aspects of cancer progression [34]. 
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Figure 2.7: Figure describing how the alteration of microRNA expression by gossypol 
treatment may contribute to the effectiveness of gossypol to inhibit MCF-7 cell 
proliferation and promote cell death.   
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Chapter 3: Gossypol Alters miRNA Expression of MCF-7 Breast Cancer Cells 
Abstract 
 
 Gossypol is a relatively new nutraceutical chemotherapeutic currently 
undergoing clinical trials for use in treating various forms of cancer.  Although the drug 
has shown effectiveness, the mechanism of action is poorly understood.  MicroRNAs 
(miRNAs) are a recently identified group of small non-coding RNAs that play an 
important role in gene regulation through their targeting of mRNAs for cleavage or 
inhibiting their translation.  When cells are treated with a variety of chemotherapeutics 
or other drugs that induce genotoxic stress, miRNA expression profiles change in 
response and are thought to modulate the effectiveness of drugs and in some cases 
promote resistance.  In this study, using a combined advanced microarray and qRT-
PCR technologies, we demonstrate a change in expression of miRNAs in response to 
gossypol in the MCF-7 cell line.  According to target analysis and previous studies, 
many of these miRNAs whose expression profiles changed have been implicated in 
processes relating to tumor suppressing as well as oncogenic activity.   
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Introduction 
Chemotherapy with cytotoxic drugs and radiotherapy are common ways to treat 
and manage breast cancer.  There are a wide variety of anticancer drugs used to treat 
breast cancer, most of which are synthetic that have targets ranging from inhibiting 
topoisomerases, raising ROS, to down-regulating the ESR etc.  One of the major 
hurdles in treating breast cancer, like most cancers, is that they gradually develop 
resistance to both chemotherapy and radiotherapy although they may be sensitive to 
synthetic drugs initially.  This resistance is due in part, to the induction of multidrug 
resistant proteins [1].   
Relatively new in its application as a chemotherapeutic, the molecular 
mechanism behind the functionality of gossypol remains to be elucidated.  Indeed 
gossypol has been shown to alter the expression of a variety of protein coding genes 
that regulate pathways like cell death [2-7], cell cycle [8-12] and oxidative stress [5, 13].  
We hypothesize that microRNA (miRNA), short non-coding RNAs that are an important 
regulatory molecule in both plants and animals, play an important role in gossypol‟s 
efficacy. miRNAs are ~18-22 nucleotides long and are transcribed in the nucleus mainly 
by RNA Polymerase II [14, 15]. 
These molecules regulate gene expression by translational repression, mRNA 
cleavage, mRNA decay by rapid deadenylation [15-17] and in some cases translational 
activation [16, 17].  The majority of miRNAs function by binding to the 3‟ untranslated 
region (UTR) of a specific mRNA transcript.  The complementarity between the miRNA 
and its prospective mRNA will decide whether the mRNA is cleaved or translationally 
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repressed [18].  In general, a fully complimentary strand will cause cleavage while a 
partially complimentary strand will induce translational inhibition [18].   
Polymerase II promoters, which include miRNA genes, many times contain 
toxicologically sensitive enhancer regions [15].   Due to this sensitivity, miRNAs are 
thought to be involved in the response of cells to genotoxic stress in a variety of 
pathways [15, 19].  Studies demonstrate that a variety of drugs alter the expression 
profiles of miRNAs in MCF-7 and other cell lines [20-23].  However, currently there are 
no studies that provide insight on the effects of gossypol on the miRNA expression 
profile of MCF-7 cells in vitro.  
 
Materials and Methods 
Cell line and cell culture 
Human MCF-7 breast cancer cells were obtained from ATCC, cultured and kept 
at 37˚C in a 5% CO2 and 95% humidified air incubator. MCF-7 cells were passaged and 
grown in Roswell Park Memorial Institute medium (RPMI) 1640 (GIBCO, Vienna, VA) 
with 10% FBS (PAA Laboratories, Dartmouth, MA), and supplemented with 4 mg/ml 
human recombinant insulin (GIBCO). The culture media was replaced every 48 hours, 
and the cells were passaged at least once a week by trypsinizing the cells using 0.05% 
trypsin/0.02% EDTA (Sigma, St. Louis, MO). 
Gossypol treatment  
Gossypol, purchased from Sigma-Aldrich (St. Louis, MO), and was kept at -80˚C 
in a dark 1.8mL tube completely impermeable to light.  Directly after purchase, a stock 
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solution of 100mM gossypol was made using DMSO as a proper solvent as it is 
insoluble in water and vacuum filtered the solution in a laminar flow hood to maintain 
sterility.   5X105 cells were plated into 12 well plates using 3 wells per treatment group 
(biological replicates) including vehicle controls in RPMI media supplemented with 10% 
FBS and absent of the use of antibiotics or antifungal compounds composing a final 
volume of all reagents to be 2mL.  After this, cells were incubated for 24 hours in just 
RPMI media without treatment allowing cells to properly adhere and stabilize.  Cells 
were exposed to  gossypol at various concentrations .  Using 0.1% DMSO to dissolve 
gossypol, it was important to use the same amount of DMSO into vehicle control and 
treatment groups to help exclude the potential effects of DMSO on the cells.  
RNA Isolation 
After treatment, MCF-7 cells were trypsinized, centrifuged, and washed with PBS 
and the remaining pellet was transferred to 1.8mL micro-centrifuge tubes.  RNA was 
extracted from the cells according to the mirVana™ miRNA Isolation Kit.  Briefly, 
samples were denatured using lysis binding buffer contained in the kit. Then, acid-
phenol extraction was used to separate RNA from DNA and other cellular components. 
After this, ethanol was added to samples and the solution was passed through a glass-
filter. Before eluting with RNase free water, the RNA was washed several times with 
wash solution. 
 Using the NanoDrop ND-1000 Micro-Volume UVVis Spectrophotometer 
(NanoDrop Technologies, Wilmington, DE), RNA was quantified in ng/µl and evaluated 
using the absorbance ratios of 260/280 and 260/230 to assess quality. 
MicroRNA Microarray 
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LC Sciences (Houston, TX) was contracted to perform the miRNA microarray. 
We sent approximately 5mg samples of total RNA to LC Sciences for analysis. Total 
RNA samples were size fractionated using the YM-100 Microcon centrifugal filter 
(Millipore, Billerica, MA) and screened for RNA sequences with <30 nt. These screened 
small RNA were extended at 3'-end with a poly(A) tail placed there by poly(A) 
polymerase, then an oligonucleotide tag to the poly(A) tail was fused  by ligation for later 
fluorescent staining. Two tags (Cy3 and Cy5) were used for two different RNA samples 
(vehicle control and gossypol treated RNA samples). Both RNA samples were 
hybridized overnight on top of an mParafloTM microfluidic chip utilizing a 
microcirculation pump (Atactic Technologies, Inc., Houston, TX). The microfluidic chips 
contained  positive control probes, detection probes and negative control probes. 
Detection probes were created in situ by photogenerated reagent (PGR) chemistry. 
Probes were composed of nucleotide coding sequences that were chemically modified 
and complementary to the 871 target miRNAs listed in the Sanger‟s miRNA miRBase, 
and additionally a spacer segment of polyethylene glycol was used to extend the coding 
sequence away from the substrate.  To ensure uniformity of conditions and sample 
labels, a combined total of 50 positive and negative control probes were used. The 
chemical modifications were done to help balance the melting temperatures of 
hybridization. The RNA hybridization process was completed using 100 ml of 6X SSPE 
buffer (0.9M NaCl, 6mM EDTA, 60mM Na2HPO4, pH 6.8) containing 25% formamide at 
348C. Post-hybridization, control and gossypol treated cells were dyed using tag-
conjugating dyes Cy3 and Cy5, respectively. To collect the fluorescent images, an Axon 
GenePix 4000B Microarray Scanner (Molecular Device, Union City, CA) was used. 
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Then the images were digitized using Array-Pro image Analysis software (Media 
Cybernetics, Bethesda, MD). To avoid dye bias, dye switching between control and 
treated RNA samples in order was performed. For accuracy, every miRNA was 
analyzed four times followed by the controls being repeated 4–16 times. 
Statistical analysis of microarray data 
The statistical analysis of the microarray data was performed by subtracting the 
background while normalizing the signals using a locally weighed regression (LOWESS) 
filter according to Bolstad et al. (2003). Detectable miRNAs were filtered by the 
following criteria: spot CV<0.5 (where CV¼standard deviation/signal intensity); signal 
intensity higher than 3X (background standard deviation); and signals from no less than 
two out of four replicates above the detection level. Statistical analysis was performed to 
identify miRNAs with expression differences between control and gossypol treated 
MCF-7 cells. The ratio between the two sets of signals (control and treated) was 
calculated and presented in log2 scale for each miRNA. miRNAs were then sorted by 
their differential ratios.  Readings of miRNAs with p-values<0.01 and log2 ratio>0.5 were 
considered significantly differentially expressed. 
qRT-PCR of miRNA expression 
TaqMan microRNA Reverse Transcription kit from Applied Biosystems (Foster 
City, CA) was used to reverse transcribe miRNAs to cDNAs. miRNA-specfic stem-loop 
primer was used to reverse trabscribe miRNAs to cDNA with a total of 200 ng RNAs. 
The composition of the other components were as follows: 0.15µL of 100mM dNTPs, 
0.19uL RNase inhibitor (20U/µL), 1 uL f primer and 1 µL multiscribe reverse 
transcriptase (50U/µL), 1.5µL reverse transcription buffer (10X), and an amount of 
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RNase free water dependent on the RNA concentration in the sample was added to 
make the final 15 µL reaction volume.   A thermal cycler was programmed to perform 
the reverse transcription according to the settings of: 16 °C-30 minutes followed by 
42°C-30 minutes, 85°C-5 minutes and finally holding the temperature upon completion 
at 4°C. The sample was then diluted with 85µL DNase/RNase-free water to prepare the 
cDNA products for qRT-PCR. 
 Five of the most up-regulated and six of the most down-regulated miRNAs were 
chosen for further analysis.  Expression levels of miRNAs were analyzed after 
performing qRT-PCR using 384-well-plates used by the ViiA™ 7 Real-Time PCR 
System (Applied Biosystem) with SYBR Green PCR master mix (SuperArray Bioscience 
Corp,Frederick, MD). Specific forward primers as well as miRNA universal reverse 
primers for miRNAs were used for quantification. Each reaction contained a total 
solution of 15µL composed of 5.5µL DNase/RNase free water, 7.5 µL SYBR Green 
master mix, 1µL cDNA, and 1uL of primer mix. At least 3 biological replicates with 3 
technical replicates for each reaction was run.  The program used for qRT-PCR began 
with the enzyme activation phase with a duration of 10 min at 95°C, followed directly by 
the denaturation phase for 15 sec at 95°C and  lastly an annealing or extension step 
with a duration of  60 sec at a temperature of 60°C. The final 2 steps were repeated for 
40 cycles. 
Target Prediction and Functional analysis 
A step by step process was used for miRNA-pathway enrichment. Initially, target 
prediction was performed for the 11 chosen miRNAs using TargetScan. Duplicates were 
removed and a list was generated that ranked 4,728 different gene targets. From this 
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point the genes were ordered from most to least commonly targeted genes. This list 
was used and inputted into DAVID. Functional annotation clustering was run with the 
highest stringency. Out of 213 clusters, only 5 clusters with enrichment values ≥3 were 
used for subsequent analysis. Next, genes were extracted from these enriched clusters 
and their order was maintained for analysis using GOrilla gene ontology software. The 
single ranked gene list was used to perform process-analysis whose output was 
summarized as „Directed Acyclic Graph‟. This presentation demonstrates the 
relationship between the pathways predicted to be altered in response to gossypol. 
Each enriched pathway had an enrichment score (E=(b/n)/(B/N) where “b” is the 
number of genes in the intersection; “n” is the number of genes in the top of the user‟s 
input list; “B” is the total number of genes associated with a specific GO term; “N” is the 
total number of genes), a p-value, and a corrected p-value (FDR). 
Next, a gene based target prediction shown in figure 3.5 and table 3.3 was based 
on targetscan. This network was constructed using genes that are commonly targeted 
by at least 8 of the 11 miRNAs chosen for further analysis. 2 genes (CCND2 and 
HIPK2) were predicted to be targeted by 9 of the 11miRNAs of interest (SS change in 
expression levels). 3 genes (IGF1, NUFIP2, and ELL2) were predicted to be targeted by 
8 miRNAs.). 
 
Results 
Gossypol alters the miRNA expression of MCF-7 cells  
Microarray 
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 Treatment with gossypol significantly altered the miRNA expression profile of 
MCF-7 cells.  891miRNAs were analyzed in this microarray study in response to 
gossypol.  Of the 891, many were discarded due to either low signal intensity or 
unacceptable statistical significance values (P>0.01).  After this filter, there were 52 
miRNAs that were up-regulated and 33miRNAs down-regulated in response to gossypol 
(Figure 3.1).  Of these miRNAs, 5 of the most up-regulated and 6 of the most down-
regulated were chosen for further analysis by qRT-PCR, these miRNAs are shown in 
table 3.1 and figures 3.3 and 3.4.   
qRT-PCR  
qRT-PCR data confirmed our miRNA microarray data and the miRNAs were 
differentally expressed in a dosage-dependent manner  
The expression of miRNAs 141, 15b, 197, 206 and 320c were significantly up-
regulated in response to treatment with gossypol.  MiR-29c was significantly down-
regulated at all concentrations and miRNA 96 was shown to be significantly down-
regulated at the 0.3μM concentration.   
miRNA targets 
 Targetscan was used as the primary means to predict miRNA targets of the 
miRNAs in this study.  From this analysis we observed multiple biological pathways 
targeted by miRNAs including: hemophilic cell adhesion, nervous system development, 
cell-cell adhesion, biological adhesion, cell adhesion, system development, 
angiogenesis, and neuron migration as seen in figure 3.2 and table 3.6.   
Next, targeting was used to construct a network using genes that are commonly 
targeted by at least 8 of the 11 miRNAs chosen for further analysis. 2 genes (CCND2 
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and HIPK2) were predicted to be targeted by 9 of the 11miRNAs of interest (SS change 
in expression levels). 3 genes (IGF1, NUFIP2, and ELL2) were predicted to be targeted 
by 8 miRNAs.) as shown in figure 3.5.  The relative function of each of these co-
targeted genes is listed in table 3.3.    
 
Discussion 
 miRNAs are proven to be an important regulatory element in cancer and have 
the ability to function as both oncogenes and tumor suppressors [24-26].  Currently, 
researchers are investigating ways to use these small noncoding RNAs as therapy for 
cancer treatments.  Its interesting to see how altering the expression of existing miRNAs 
in response to gossypol may contribute to the overall mechanism of action and efficacy 
of the nutraceutical.   
 This study reveals the first information about the alteration of miRNA expression 
in response to gossypol ever done in human breast cancer cells.   Its well-known that a 
variety of toxological stressors induce changes in miRNA expression which in turn 
mediate a response as shown in figure 3.7 [20, 21, 23, 27, 28].   
 Interestingly, miRNAs that show altered gene expression in both the microarray 
and the multiple dose qRT-PCR analysis have been implicated previously to affect a 
variety of biological pathways related to cancer including many of those predicted by 
Targetscan (Tables 3.2 and 3.3 and Figures 3.5 and 3.6).  In particular, miR-141 of the 
miR-200 miRNA family was found to be one of the most up-regulated in both the 
microarray study and qRT-PCR study.  Previous literature demonstrates that this 
miRNA is likely to be involved in targeting two E box factors ZEB1 and ZEB2 which are 
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both key regulators within a complex network of transcriptional repressors that regulate 
the expression of E-cadherin and a number of master regulators of epithelial polarity 
[29-31].  Due to this targeting,miRNA 200 family has been implicated to be involved as 
both a marker and a powerful regulator of epithelial-to-mesencymal transition (EMT) 
[32, 33]. These effects can be seen in figure 3.8 which additionally shows the targets of 
the let-7 family which in our microarray study (let-7f) was shown to be up-regulated also 
as seen in figure 3.1 [33].   
 Additionally up-regulated miRNAs from this study seen in literature are miR-15b, 
miR-206 and miR-320c.  Current literature suggests that miR-15b likely targets BCL-2 a 
well-known mechanism of gossypol‟s ability to initiate cell death and cyclins contributing 
to controlling cell cycle progression [23, 34, 35]. miR-206 is well documented in its role 
in suppressing the human estrogen receptor alpha (ERα) [36-38].  Numerous studies 
demonstrate that their expression is inversely related and some support evidence of a 
double negative feedback loop between the two.  Additionally, it has been shown that 
ER+ breast cancers express far lower amounts of miR-206 than normal cells. miR-320c 
has been implicated as a biomarker for gastric cancer.  When miR-320c is expressed at 
very low levels studies show this is a strong indicator of gastric cancer, with some 
demonstrating this expression pattern in liver and brain cancers as well [39-41].   
 miRNAs that were significantly down-regulated miRNAs in this study are miR-29c 
and miR-96.  MiR-29c, which was down-regulated in all 4 dosages of gossypol when 
compared to the vehicle control (figure 3.4), has been looked at as a possible biomarker 
for breast cancer as well as a contributor to drug resistance [42-44].  Although only 
down-regulated in the 0.3µM treatment group, miR-96 up-regulation has been 
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associated with the proliferation and anchorage-independent growth of breast cancer 
cells as well as preventing apoptosis induction via the FOXO1 pathway [45, 46].   
 Taken together, it is clear that gossypol induces an aberrant change in 
expression of a variety of miRNAs.  The miRNAs chosen for further analysis affect a 
variety of different biological pathways involved in cancer progression (figure 3.5 and 
3.6).  Figure 3.9 demonstrates miRNAs that exhibited altered expression in response to 
gossypol treatment and their known targets found throughout literature and mentioned 
above.  From this data, we see how changes in miRNA expression levels in response to 
gossypol contribute to its overall efficacy.  Additionally, the miRNA targeting data with 
the most enriched pathways relating to cell adhesion (table 3.2) combined with 2 out of 
the 5 confirmed up-regulated miRNAs (figure 3.4 and 3.9) targeting the EMT pathway 
presents evidence gossypol may be an effective treatment for preventing cancer 
progression and metastasis.   
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Table 3.1: Table demonstrating the 11 miRNAs chosen for further analysis by qRT-PCR 
and the total amounts of predicted mRNA targets for each.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
miRNA Number of predicted targets 
hsa-let-7f 819 
hsa-miR-141 531 
hsa-miR-15b 968 
hsa-miR-197 140 
hsa-miR-19a 938 
hsa-miR-206 584 
hsa-miR-30e 1080 
hsa-miR-320b 539 
hsa-miR-320c 539 
hsa-miR-96 787 
hsa-miR-29c 1078 
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Table 3.2: Pathways associated with the 11 miRNAs chosen for further study in order 
from highest to lowest enrichment values (E=(b/n)/(B/N) where “b” is the number of 
genes in the intersection; “n” is the number of genes in the top of the user‟s input list; 
“B” is the total number of genes associated with a specific GO term; “N” is the total 
number of genes), a p-value, and a corrected p-value (FDR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Description P-value FDR q-value Enrichment (N, B, n, b) 
     
homophilic cell adhesion 1.31E-18 6.84E-16 12.69 (203,16,14,14) 
nervous system development 1.09E-14 3.15E-12 11.28 (203,18,12,12) 
cell-cell adhesion 5.30E-16 1.97E-13 10.15 (203,20,14,14) 
biological adhesion 2.85E-12 6.74E-10 6.34 (203,32,14,14) 
cell adhesion 2.85E-12 6.18E-10 6.34 (203,32,14,14) 
system development 3.02E-10 5.61E-08 6.34 (203,32,12,12) 
cell development 4.82E-06 5.02E-04 3.69 (203,10,55,10) 
angiogenesis 8.48E-05 4.70E-03 3.17 (203,9,64,9) 
neuron migration 3.43E-05 2.29E-03 3.12 (203,10,65,10) 
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Table 3.3:  This network was constructed using genes that are commonly targeted by at 
least 8 of the 11 miRNAs chosen for further analysis. 2 genes (CCND2 and HIPK2) 
were predicted to be targeted by 9 of the 11miRNAs of interest (SS change in 
expression levels). 3 genes (IGF1, NUFIP2, and ELL2) were predicted to be targeted by 
8 miRNAs.). 
 
 
ID Gene Name Summary of Functions 
CCND2 cyclin D2 cell cycle, cell cycle control, cell division, complete 
proteome, cyclin, polymorphism, G1/S-specific cyclin-D2 
ELL2 elongation factor, RNA 
polymerase II, 2 
3d-structure,complete proteome, elongation 
factor,nucleus,phosphoprotein,polymorphism,Transcriptio
n,transcription regulation 
HIPK2 homeodomain interacting 
protein kinase 2 
alternative splicing, apoptosis, atp-binding, complete 
proteome, cytoplasm, isopeptide bond,kinase,nucleotide-
binding,nucleus,phosphoprotein,polymorphism,serine/thr
eonine-protein kinase, transcription, transcription 
regulation, transferase, ubl conjugation 
IGF1 insulin-like growth factor 1 
(somatomedin C) 
3d-structure,alternative splicing, amidated carboxyl end, 
complete proteome, deafness, direct protein sequencing, 
disulfide bond, growth factor, plasma, polymorphism, 
secreted, signal 
NUFIP2 nuclear fragile X mental 
retardation protein 
interacting protein 2 
acetylation, complete proteome, cytoplasm, direct protein 
sequencing, nucleus, phosphoprotein, RNA-binding 
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Figure 3.1: Log2  graphs demonstrating fold change in expression of significantly altered 
miRNAs between gossypol treated and non-treated MCF-7 cells p<.001. 
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Figure 3.2: Heat map demonstrating fold change in expression of significantly altered 
miRNAs between gossypol treated and non-treated MCF-7 cells p<.001. The brighter 
the green in color represents higher up-regulation, while the brighter the red in color 
represents down-regulation. 
64 
 
Figure 3.3: Heat map demonstrating fold change in expression of 11 miRNAs chosen 
for further study between gossypol treated and non-treated MCF-7 cells p<.001. The 
brighter the green in color represents higher up-regulation, while the brighter the red in 
color represents down-regulation. 
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Figure 3.4: Fold change of qRT-PCR analysis of 11 chosen miRNAs at 4 different 
concentrations (0.1 μM; 0.3μM; 1μM; 3μM) (* = p<0.05 compared to VC).   
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Figure 3.5: Network using genes that are commonly targeted by at least 8 of the 11 
miRNAs chosen for further analysis. Hexagons are the protein coding genes, circles are 
the miRNAs.  2 genes (CCND2 and HIPK2) were predicted to be targeted by 9 of the 
11miRNAs of interest (SS change in expression levels). 3 genes (IGF1, NUFIP2, and 
ELL2) were predicted to be targeted by 8 miRNAs.).  The node size is scaled such that 
it is proportional to the number of interactions. The highest being 9 (e.g. CCND2) and 
the lowest being 1 (e.g. hsa-miR-29c). 
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Figure 3.6: Directed acyclic graph that shows the relationship between enriched pathways predicted to be affected in 
response to gossypol.  
68 
 
 
Figure 3.7: MicroRNAs, Chromatin, Stress and Expression. Various stresses mediate 
multiple signaling pathways. MiRNAs that regulate Dicer and chromatin are components 
of stress pathways that regulate gene expression patterns (Image from 
roswellpark.edu). 
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Figure 3.8: Model to illustrate how let-7 and miR-200 could each contribute to tumor 
progression, one by controlling let-7 regulated oncofetal genes (LOGs) and the other by 
regulating EMT and metastasis. Crosstalk exists between the pathways that regulate 
reverse embryogenesis and EMT [33]. 
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Figure 3.9: Summary of the major targets found in literature of miRNAs whose 
expression was altered in response to treatment with gossypol.   
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Chapter 4: Effects of gossypol on oxidative stress in MCF-7 cells 
Abstract 
 Many chemotherapy drugs today utilize the generation of reactive oxygen 
species (ROS) to induce cell death in cancer cells.  In general, this strategy is very 
effective initially, but with time cancer cells tend to develop a strong resistance to ROS 
through up regulation of their antioxidant defense system.  When treated with gossypol, 
a polyphenolic aldehyde found in high concentrations within cotton seed oil, many 
cancer cells are unable to procure this resistance and in many cases gossypol has been 
able to lower their resistance to other drugs [1-3].  In this study, using qRT-PCR 
technology followed by protein analysis of several key elements involved in oxidative 
stress, we examined if gossypol may indeed decrease the resistance of MCF-7 cells to 
ROS via their antioxidant defense systems.  Our results indicate that gossypol does 
seem to have a profound effect on the antioxidant defenses of MCF-7 cells on both 
mRNA and protein levels.  When treated with gossypol, MCF-7 cells exhibited signs of 
oxidative stress as well as an inability to deal with this stress using key antioxidant 
enzymes.  This data combined with other studies leads us to believe that generation of 
ROS plays a big role in the efficacy of gossypol in treating breast cancer solitarily and 
may also be a big part of its success when combined with other chemotherapy drugs.  
This study helps to elucidate which candidate chemotherapeutics may be more effective 
in combination with gossypol.   
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Introduction 
 Oxidative stress is a common term used to describe the stress placed on cells 
due to an imbalance in the relationship between oxidants and their antioxidant defense 
systems.  Oxidants are chemical compounds that are good electrophiles or that gain 
electrons easily when undergoing a redox reaction.  Reactive oxygen species (ROS), 
reactive nitrogen species (RNS) and electrophilic metal ions have undergone extensive 
study in the biological science field.  Important biological molecules like DNA, lipids and 
proteins, are nucleophilic due to their phosphate, sulfur and nitrogen enriched structures 
making them susceptible to electrophilic attack.  These attacks result in DNA damage, 
lipid peroxidation and protein dysfunction [4]. 
 ROS present in the body, play a major role in various cell-signaling pathways [5-
7].  Studies have shown that ROS can be associated with risk factors of chronic 
diseases like cancer, such as tobacco, stress, radiation, environmental pollutants , viral 
infection, bacterial infection and diet that impact cells through the generation of ROS [8, 
9].  
Rather complexly, even though excess ROS from many different sources 
contributes to the induction of many cancers, they also seem to mediate the mechanism 
of action of many chemotherapeutic agents [10].  ROS have been associated with the 
anti-tumor and chemopreventive action of nutraceutcials that are extracted from many 
natural molecules used today in traditional medicine.  With this knowledge, we 
understand that ROS can function as both cancer-suppressors and the function of 
cancer-promoters depends on the dosage of ROS [10].   
76 
 
In general, cancer treatment strategies utilizing ROS inducing chemotherapies show 
initially very successful results, but as time goes on cancer cells often develop a strong 
resistance to oxidative stressors by up-regulating their antioxidant defense systems 
(Figure 4.1).  Some examples of key enzymes involved in this defense and related to 
this study are catalase (Cat) and superoxide dismutase (SOD)  which act to eliminate 
free radicals and prevent DNA damage and the activation of apoptotic signaling 
pathways [11, 12].  If gossypol successfully inhibits this resistance, then new strategies 
using combination drug therapy with ROS inducing chemotherapeutics like 5-
Fluorouracil or As2O3 can help overcome this limitation.    
ROS have been demonstrated to be effector molecules of many pathways 
ending in cellular death (Figure 1.5) [13] .  One of the first lines of defense when cells 
are faced with oxidative stress is autophagy.  In this strategy of defense, cells can utilize 
a mechanism of selective lysosomal self-digestion of their intracellular components to 
help maintain cellular homeostasis.  However, when exposed to higher levels of ROS, 
cells usually resort instead to the activation of autophagy induced cell death pathways 
[5, 7, 14].  ROS inducing apoptosis can be initiated by extracellular death receptors 
(extrinsic pathway) or through the intracellular mitochondrial signaling pathway (intrinsic 
pathway).  With the extrinsic signaling pathway, ROS are induced by the Fas ligand and 
are required for Fas phosphorylation and activation [10].  In the intrinsic pathway, ROS 
act to open the permeability transition pore of mitochondria by utilizing the activating 
pore-destabilizing proteins (Bcl-2-associated X protein, Bcl-2) and inhibiting pore-
stabilizing proteins (Bcl-2 and Bcl-xL) [6]. Additionally, in many cases if ROS levels are 
high enough, cells will undergo necrosis.  ROS are key factors involved in the 
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propagation and execution phases of necrotic cell death, they can damage proteins, 
DNA and lipids either directly or indirectly, which can result in the disruption of the 
integrity of organelles and the cell as a whole. When cells are undergoing necrosis, they 
initiate a release of pro-inflammatory signaling cascades via the release of pro-
inflammatory cytokines and by a sporadic emptying of their cellular contents upon lysing 
[15-18].  In this study, we investigated the effect of gossypol on oxidative stress-related 
proteins at both mRNA and enzyme activity levels in the human breast cancer line, 
MCF-7, in vitro. 
 
Materials and Methods 
Cell line and cell culture 
Human MCF-7 breast cancer cells were ordered from ATCC and placed in a 
humidified 5%CO2 and 95% air incubator at 37˚C.  Roswell Park Memorial Institute 
medium (RPMI) 1640 (GIBCO, Vienna, VA) media was used to grow MCF-7 cells and it 
was supplemented with 10% FBS (PAA Laboratories, Dartmouth, MA), and 4 mg/ml 
human recombinant insulin (GIBCO). A media change was performed at least every 48 
hours, and the cells were trypsinized and passaged once a week by using 0.05% 
trypsin/0.02% EDTA (Sigma, St. Louis, MO). 
Gossypol treatment  
Gossypol was ordered from Sigma-Aldrich (St. Louis, MO) and kept at -80˚C in a 
dark 1.8 mL micro-centrifuge tube impermeable to light.  A 100 mM stock solution of 
gossypol was created using DMSO as the solvent and the entire procedure was 
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performed in a laminar flow hood and the solution was vacuum filtered to maintain 
sterility.  To prepare cells for treatment, 5X105 cells were plated into 12 well plates with 
3 wells per treatment group including controls in RPMI media with 10% FBS and no 
antifungal compounds or antibiotics with a final volume of 2mL in each well.  Initially, 
cells were incubated for 24 hours in the RPMI media described above without treatment 
to allow for adhesion and stability.  After stabilization and adherence, cells were treated 
with gossypol using DMSO as a vehicle.  A 0.1% DMSO concentration was maintained 
in both the vehicle control and the treatments to exclude potential effects of DMSO.  
RNA Extraction, Reverse Transcription, Real Time PCR 
Forty-eight hours post-treatment, cells were trypsinized, centrifuged, washed with 
PBS and the pellet was placed in 1.8 mL micro-centrifuge tubes.  RNA was extracted 
from cells using the mirVana™ miRNA Isolation Kit.  The sample cells were denatured 
using a lysis binding buffer. Then, the RNA was separated from DNA and other cellular 
lipids and proteins via acid-phenol extraction. Next, ethanol was added to each sample, 
immediately followed by passing the solution through a glass-filter.   To purify the RNA, 
several washes preceded the addition of elution solution used to elute the RNAs. 
To quantify and evaluate the quality of RNAs extracted, a NanoDrop ND-1000 Micro-
Volume UVVis Spectrophotometer (NanoDrop Technologies, Wilmington, DE) was used 
to determine RNA concentration and the quality of the RNA which is  based on the 
absorbance ratios of 260/280 and 260/230. 
Next, reverse transcription was performed using TaqMan microRNA Reverse 
Transcription kit from Applied Biosystems (Foster City, CA) to create cDNAs. For 
protein coding genes, the poly-T primer was used. 200 ng RNAs was used for each 
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reverse transcription reaction. The other reagents within the reaction are as follows: 
0.15µL of 100mM dNTPs, 2µL of poly (T) primer, 0.19uL RNase inhibitor (20U/µL), 
1.5µL of reverse transcription buffer (10X), and 1 µL of multiscribe reverse transcriptase 
(50U/µL) and RNase free water was added based on the concentration of RNA in the 
sample to make the final 15 uL reaction volume. A thermal cycler was used to perform 
the reverse transcription reaction and was programmed as follows: 16 °C for 30 minutes 
followed by 42°C for 30 minutes, 85°C for 5 minutes and finally, a hold phase at 4°C. To 
prepare the cDNA for qRT-PCR, the sample was then diluted in 85µL DNase/RNase-
free water. 
qRT-PCR was conducted on 384-well-plates using the ViiA™ 7 Real-Time PCR 
System (Applied Biosystem) using SYBR Green PCR master mix (SuperArray 
Bioscience Corp,(Frederick, MD). To amplify cDNAs of the protein coding genes 
created in the previous step, forward and reverse specific primers were designed and 
used. Then, qRT-PCR was performed with each well containing a total of 15µL of total 
reaction mixture made up of the compilation of 7.5µL SYBR Green master mix, 1µL 
primer mix, 5.5µL DNase/RNase free water, 1µL cDNA.  qRT-PCR was conducted with 
at less 3 biological replicates with a corresponding 3 technical replicates each. The 
actual program used for qRT-PCR began by activating the enzyme for 10 minutes at 
95°C followed by a denaturation step for 15 seconds at 95°C, then by an 
annealing/extension step for 60 seconds at 60°C. The final 2 steps were repeated for 40 
cycles. 
Treatment and Sample Preparation for Protein Assays 
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Gossypol was purchased from Sigma-Aldrich (St. Louis, MO) and stored at -80To 
maintain consistency, and provide the larger amount of cells necessary for protein 
assays, the same ratio of cells to surface area was used as all other assays.  Instead of 
Corning 12-well plates, 9.35X10^6 cells were seeded in T-75 Corning Canted Neck Cell 
Culture Flasks, one biological replicate per flask.  Cells were first incubated for 24 hours 
in RPMI media with no treatment to allow for adhesion and stability.  Next, cells were 
treated at varying concentrations of gossypol using DMSO as a vehicle.  Since 0.1% 
DMSO was used in each treatment group, the same amount of DMSO was also added 
to the control groups to exclude potential effects of DMSO.  Forty eight hours post-
treatment, media was removed and cells were washed three times with PBS free of 
Ca2+ and Mg2+ for 30 seconds.  After the final wash, cells were removed using a rubber 
policeman and centrifuged at 200g 4˚C in 1.5-mL centrifuge tubes.  Supernatant was 
removed and cells were re-suspended in three times the pellet volume in Phosphate 
Buffer (PB, pH 7.8) and sonicated on ice for ~30 seconds at low power.   
Protein concentrations of samples were calculated using the Thermo 
Scientific™Pierce™BCA Protein Assay according to the manufacturer‟s protocol and 
utilizing the 96-well Fisher Scientific Multiskan®. MCC/340 Microplate Reader 
measuring absorbance at 562 nm.   
Catalase Assay 
 Catalase activity was measured according to a previous method with a small 
modification [19].  Catalase removes peroxide at an exponential rate.  Using a 
Shimadzu UVmini-1240 UV/Visible Scanning Spectrophotometer, a kinetics program 
was set to record every 30 seconds at 240 nm for 2 minutes.  The Spectrophotometer 
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was calibrated using a 3-mL quartz cuvette filled with 3-mL of Phosphate Buffer pH 7.8.  
Next, the biological replicates and the bovine liver catalase standard were mixed with 
the Hydrogen Peroxide working solution and the kinetics program was performed 
according to a previous protocol [20] using 3 biological replicates with 3 technical 
replicates.   
SOD Assay 
 Xanthine-Xanthine Oxidase was used to generate superoxide and nitroblue 
tetrazolium (NBT) reduction was used as an indicator of superoxide production. SOD 
competes with NBT for superoxide; therefore, the percentage inhibition of NBT 
reduction is a measure of the amount of SOD present (Figure 4.2).  A modified method 
was used to determine the activity of SOD per mg of protein using a 96-well Fisher 
Scientific Multiskan®. MCC/340 Microplate Reader.  Reagents and Solutions needed for 
this assay were purchased and prepared according previous reported protocol [20].  A 
kinetics program was used to calculate the absorbance/minute of reduced NBT at 
560nm.  An XO control was prepared and adjusted with DETAPAC to a measurement 
between 0.02 and 0.025 absorbance/minute.  Once properly calibrated, the control was 
used as a baseline for NBT reduction free from competition from superoxide.  A serial 
dilution with Phosphate Buffer pH 7.8 was conducted for each sample using 3 biological 
replicates and 3 technical replicates to assess the % inhibition as a function of protein 
concentration.   
GCL and GSH Assay 
Reagents used in the study include sucrose, Tris base, ethylenediamine tetra-
acetic acid (EDTA), boric acid, L-serine, magnesium chloride hexahydrate (MgCl2), 
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adenosine 5'-triphosphate disodium (ATP), L-glutamic acid, L-cysteine, 5-sulfosalicylic 
acid dihydrate (SSA), sodium hydroxide (NaOH), naphthalene-2,3-dicarboxaldehyde 
(NDA), dimethyl sulfoxide (DMSO) and gamma- glutamylcysteine (GC). Sodium 
hydroxide was obtained from Fisher Scientific International Inc. (Fair Lawn, NJ, USA), 
while all others were purchased from Sigma Co. (St. Louis, MO, USA).  
The GCL reaction cocktail contained 400mM Tris, 2mM EDTA, 20mM boric acid, 
2mM L-serine, 40mM MgCl2, 40mM ATP and L-glutamic acid, with a pH of 7.4. The 
concentration of glutamic acid in reaction cocktail was 40mM, and the concentration of 
cysteine was 30mM based on the previous report [21].  
Fifty µl of cell homogenate, 50 µl of GCL reaction cocktail and 50 µl of cysteine 
were added sequentially, then incubated for 30 minutes at 37°C, after which, 50 µl of 
200mM SSA were added to terminate the reaction. For GSH background measurement, 
50 µl of 200mM SSA were added prior to the addition of GCL reaction cocktail and 
cysteine.  
The mixture was then centrifuged at 2,000g for 10 minutes at 4°C. The resulting 
supernatant was used for the following derivation. Twenty µl of supernatant were loaded 
into a clear-bottomed black 96-well microplate, followed by the addition of 180 µl of NDA 
solution (1:1:7 of 10mM NDA : 0.5M NaOH : 0.05M Tris with a pH of 10.0, v/v/v), the 
mixture was incubated in the dark at room temperature for 30 minutes. The 
fluorescence intensities of GSH-NDA and the sum of GC-NDA and GSH-NDA were 
measured at 485nm excitation and 538nm emission on a fluorescence plate reader 
(Molecular Devices, CA, USA, 1996), the difference was the GC-NDA content. 
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 To assess the concentration of GSH in relation to the fluorescence, a standard 
curve was performed and is shown in figure 4.7.  Using the standard curve, both GSH 
and GCL concentrations could be obtained due to their lack of difference in fluorescent 
activity as demonstrated by White [22].   
 A GSH standard curve was used for the quantification of both GCL and GSH in 
relation to fluorescence intensity.  As shown in figure 4.7, a series of seven 2-fold 
dilutions were calculated beginning with 1000µM GSH and ending with 15.625µM GSH 
with the last and final point void of GSH.  Three replicates of each concentration were 
used and the R2 value for the standard curve was 0.9984 as seen in figure 4.7.    
 
 
Results 
qRT-PCR 
 Figure 4.3 shows the results from qRT-PCR analysis of key genes relating to 
oxidative stress in MCF-7 breast cancer cells after treatment at four concentrations   
(0.1µM, 0.2µM, 1µM, 3µM) of gossypol.  We observed an overall downward trend in 
gene expression as the dosages of gossypol increased.  Catalase (CAT), cytochrome 
p450 (CYP2U1), glutathione synthetase (GSS) and glutathione S-transferase theta 1 
(GSTT1) all had similar patterns of a slight down-regulation in response to gossypol with 
significances of p< 0.033.  With glutathione peroxidase (GPX1), nicotanimide adenine 
dinucleotide phosphate (NADPH) and superoxide dismutase (SOD1) ,we see a distinct 
up-regulation of the 0.1µM treatment followed by a pattern of decrease in expression as 
concentrations increased with p values <0.013.   
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Catalase Assay 
 Catalase activity decreases as treatment concentration with gossypol increases 
(Figure 4.4).  This decrease is consistent with the gene expression data from the qRT-
PCR analysis (Figure 4.3).  The protein activity of catalase is expressed as U/mg 
protein with the vehicle control having an average activity of 2.99 U/mg; the 0.1µM 
gossypol treatment demonstrated an average activity of 2.29U/mg and finally the 
highest concentration of gossypol at 3µM exhibited the lowest average activity of 1.94 
U/mg.   
SOD assay 
 Similar to catalase, SOD activity was decreased proportionally to the 
concentration of gossypol treatment.  The vehicle control displayed an average activity 
of 43.39 U/mg; the 0.1µM gossypol treatment exhibited an activity of 55.52 U/mg a 
slight but not statistically significant increase and at the highest concentration of 
gossypol 3µM, we observed a strong statistically significant (p=0.01) decrease to an 
average activity of 8.06 U/mg (Figure 4.5 D).  Figures 4.5 A, B, C are graphs that show 
the % inhibition of NBT reduction versus µg of protein for VC, 0.1µM and 3µM. 
GCL and GSH assay 
 Gossypol tretament increased the activity of GCL and the levels of GSH at even 
the lowest treatment (0.1µM) and even further at the 3µM treatment.  We saw that the 
increase in GCL activity and GSH levels correlated well, which beyond statistical tests is 
a good indicator the assay was effective due to their interrelatedness.  Average GCL 
activity was 0.364 measured in nmole/minute/milligrams protein for the vehicle control; 
0.591 at the 0.1µM gossypol treatment and finally 0.693 for the 3µM treatment.  GSH 
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levels measured in µM/µg in a similar manner had average levels of 1.80 for the vehicle 
control, 2.98 for the 0.1µM gossypol treatment and finally 2.71 at the 3µM treatment.  
 
Discussion 
 In this study, we observed the down-regulation of many antioxidants in response 
to gossypol.  However, with enzymes like SOD and GCL, a period of up-regulation 
seems to occur in response to gossypol treatment, with SOD at the lower concentration 
of 0.1µM consistent at both the genotypic and protein level (figures 4.3, 4.5 respectively) 
and with GCL and levels of GSH at both treatment levels (figure 4.6: 0.1µM, 3µM).  
Although it would be more desirable from a combination therapy standpoint to see a 
complete down-regulation of all antioxidant defenses, this data does suggest that not 
only does gossypol reduce the efficacy of key antioxidants at the right concentration 
(3µM) but that gossypol is simultaneously creating oxidants and stressing MCF-7 cells 
which is not unexpected due to its structure.  Previous studies have shown gossypol is 
very capable at both inhibiting oxidative stress related enzymes as well as inducing 
oxidative stress [23-25].   
 An emerging strategy in cancer treatment is to enhance the oxidative stress 
placed on cancer cells by inhibiting elements of their antioxidant defense systems.  
Using anticancer agents that target SOD in particular has shown great promise in 
utilizing this strategy.  2-Methoxyestradiol [26-28] for metastatic breast cancer and 
prostate cancer , ATN-224 for prostate cancer [29] have undergone phase I and II 
clinical trials respectively as drugs that specifically inhibit superoxide dismutase enzyme 
activity in cancer cells.  Some anticancer compounds also target the GSH system.  β-
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Phenylethyl isothiocyanate (PEITC) a mustard oil, was shown to deplete levels of GSH 
and inhibit the activity of GPx [30].  Buthionine Sulfoximine (BSO) specifically inhibits 
GCS which in turn inhibits GSH levels downstream.  It was found to be safe and 
effective in a phase I study where it was combined with melphalan an alkylating 
chemotherapeutic [31].  BSO has also been used in combination with As2O3 in the 
successful treatment of advanced stage solid tumors [32].   
 Additionally, gossypol has been shown to induce cell death utilizing its oxidant 
generating ability in a variety of cell lines [24, 33, 34].  It appears from the results of this 
study that cells did in fact experience oxidative stress in response to gossypol and 
certain key antioxidants were simultaneously inhibited.  Due to these results, a more 
accurate assessment of the oxidative effects of gossypol on MCF-7 breast cancer cells 
has been achieved.  These results indicate the possibility of a dual role of gossypol 
inhibiting SOD and CAT, the main eliminators of superoxide and hydrogen peroxide 
respectively, and inducing cell death mediated by generation of ROS.  Due to 
gossypol‟s unique ability to simultaneously inhibit these key antioxidant enzymes and 
induce oxidative stress, a combination therapy with a superoxide generating 
chemotherapy like As2O3   which has had success in treating leukemia  [35, 36] and 
advanced solid stage tumors in combination with BSO [32] is suggested to optimize 
their results and possibly create a synergistic effect that is more successful than either 
drug solitarily.   
  
87 
 
 
 
Figure 4.1: A schematic of the three major types of primary intracellular antioxidant 
enzymes in mammalian cells: SOD, catalase, and peroxidase. The SODs convert O2 •- 
into H2O2, while the catalases and peroxidases convert H2O2 into water [20].  
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Figure 4.2: Schematic for the method used to determine the SOD activity utilizing the 
ability of SOD to inhibit the reduction of NBT.  Under normal conditions, Xanthine 
Oxidase produces superoxide when substrates Xanthine and O2 are present.  However, 
when active Superoxide Dismutase is present it competes for Superoxide; thus 
inhibiting the normal rate at which NBT is reduced.   
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Figure 4.3: Effect of gossypol on the expression of genes relating to oxidative stress.  
When treating with gossypol at 4 different concentrations (0.1µM, 0.2µM, 1µM, and 
3µM), a general downward trend is observed that is proportional to the dose (* = p<0.05 
compared to VC). 
 
* * * 
* 
* 
* 
* * * 
* 
* * * * * * * * 
-2
0
2
4
6
8
10
12
CAT CYP2U1 GPX1 GSS GSTT1 NADPH SOD1
Fo
ld
 C
h
an
ge
 
0.1µM
0.3µM
1µM
3µM
90 
 
 
Figure 4.4: Catalase enzyme activity measured per milligram protein.  Post-treatment 
with gossypol a downward trend of enzyme activity was observed proportional to the 
dosage of treatment.  Catalase activity was measured by a spectrophotometric 
procedure measuring peroxide removal according to the method of Beers and Sizer [19] 
(Different letters=statistically significant difference P<0.05).  
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Figure 4.5: SOD activity/mg (0.1µM, 3µM) concentrations (Different letters=statistically significant difference P<0.05). 
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Figure 4.6: GCL activity and GSH level responses to treatment with gossypol (0.1µM, 
3µM).   Gossypol stimulates slightly the protein expression of GCL and GSH indicating a 
response to oxidative stress induced by the drug.  (Different letters=statistically 
significant difference, capital letters comparing GSH levels and lower case letters for 
GCL activity P<0.05) 
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Figure 4.7: GSH standard curve conducted using 2 fold dilutions starting at 1000µM.  
This curve helped to standardize the RFU per µM of GSH-NDA and GCL-NDA.   
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